de la Cruz Jennifer, Canal Clinton
At Mercer University in Atlanta, Ga., Jennifer de la Cruz is a clinical assistant professor in the PA program and Clinton Canal is an assistant professor in the College of Pharmacy's Department of Pharmaceutical Sciences. The authors have disclosed no potential conflicts of interest, financial or otherwise.
JAAPA. 2019 Jan;32(1):44-45. doi: 10.1097/01.JAA.0000547757.46299.3d.
Pimavanserin is a first-in-class selective serotonin 5-HT2A receptor inverse agonist approved for the treatment of Parkinson disease psychosis. This article discusses pimavanserin's mechanism of action, which patients are appropriate candidates for therapy, adverse reactions, and appropriate dosing.
匹莫范色林是首个获批用于治疗帕金森病精神病的选择性5-羟色胺5-HT2A受体反向激动剂。本文讨论了匹莫范色林的作用机制、哪些患者适合接受该疗法、不良反应及合适的剂量。
